Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway

Key points

• AU$10 million secured to support DMX-200 commercial manufacturing
• Dimerix funded through ACTION3 Phase 3 trial completion
• Phase 2 trial initiation for DMX-652 in acute kidney injury

Full summary

Dimerix Ltd, a clinical-stage biopharmaceutical company, has secured a AU$10 million non-dilutive loan facility from SKIPTAN Pty Ltd, an associate of a substantial shareholder, to support its clinical trials. This funding will aid in commercial manufacturing of DMX-200, expanded access programs, and the initiation of a Phase 2 trial for DMX-652, a new asset for acute kidney injury. Dimerix is now funded through the completion of the ACTION3 Phase 3 trial for DMX-200 and the Phase 2 trial for DMX-652. Negotiations are ongoing for up to an additional AU$40 million in non-dilutive funding to extend the cash runway beyond these trials.